How to Develop Estrogen Receptor Alpha (ERα) PROTACs: Target Selection, Warhead Selection, and Linker Design

* Please be kindly noted that our services and products are intended for research use by organizations or companies and are not intended for individual use.

Consult with Our Experts

What Is Estrogen Receptor Alpha (ERα), and Which Receptor Forms Are Suitable for PROTAC Development?

Estrogen receptor alpha (ERα), encoded by the ESR1 gene, is a ligand-dependent nuclear receptor and transcription factor that regulates gene expression in response to estrogen. Following binding to 17β-estradiol (E2), ERα undergoes conformational changes, forms receptor dimers, recognizes estrogen response elements (EREs) in DNA, and recruits transcriptional cofactors. Its activity depends on receptor abundance, ligand-binding properties, domain organization, and interactions with other proteins. These features make ERα a well-established target for targeted protein degradation, but they also create several distinct opportunities for PROTAC design.

Full-length ERα, commonly referred to as ERα66, contains approximately 595 amino acids and is organized into six structural regions (A–F). The N-terminal A/B region contains the activation function 1 (AF-1) domain, which contributes to ligand-independent transcriptional activity. The C region contains the DNA-binding domain (DBD), which recognizes specific ERE sequences through two zinc-finger motifs. The D region is the flexible hinge that connects the DBD and ligand-binding domain (LBD). The E region contains the LBD and activation function 2 (AF-2), while the C-terminal F region contributes to receptor interactions and regulatory functions.

The LBD is the most established starting point for conventional ERα PROTAC development because it contains a defined orthosteric ligand-binding pocket. However, several structural and biological characteristics make alternative approaches relevant. ESR1 mutations can change the conformation of the LBD, truncated receptor forms may lack parts of the conventional ligand-binding region, and the DBD provides an independent recognition site. In addition, protein-interaction surfaces and partially disordered receptor regions offer opportunities for emerging degrader architectures.

Several ESR1 alterations deserve particular attention. Y537S and D538G are prominent LBD mutations that stabilize an agonist-like receptor conformation and promote ligand-independent activity. Other substitutions, including Y537C, Y537N, E380Q, and L536P, have also been investigated in ERα degrader research. These mutations do not produce identical structural effects, so the binding behavior of a PROTAC warhead should be assessed against each intended receptor form.

Table 1. ERα Structural Domains, Receptor Forms, and PROTAC Development Implications.

For most small-molecule ERα degrader programs, wild-type LBD-directed development remains the most practical starting point. Mutation-targeted and DBD-directed approaches are important when the objective is to maintain degradation across altered receptor conformations or avoid dependence on the conventional ligand-binding pocket. ERα36 and ERα46 should be treated as separate design targets because their retained domains, localization, and functional properties are different.

Overview of Developed ERα PROTACs and Their Molecular Design

ERα PROTAC research has progressed from early antagonist-based bifunctional molecules to more sophisticated designs using optimized receptor-binding ligands, alternative E3 ligase recruiters, and different linker architectures. The main research approaches include raloxifene-derived VHL-recruiting degraders, lasofoxifene-based CRBN-recruiting compounds, SERD-derived VHL degraders, and nucleic acid-based PROTACs that recognize the DBD.

Several representative compounds illustrate how changes in the target-binding scaffold and E3 recruitment system influence ERα degradation. More recent work has also investigated molecular glue-based PROTAC architectures that recruit protein complexes containing ERα, extending the design space beyond direct occupation of a conventional ligand-binding pocket.

Table 2. Representative Developed ERα PROTACs and Their Molecular Design Features.

These examples illustrate several important differences in ERα degrader design:

• Target-binding scaffold: Raloxifene-, lasofoxifene-, and SERD-derived ligands provide structurally different approaches to recognizing the ERα LBD.
• E3 ligase recruitment: VHL and CRBN are the best-supported starting points in the representative ERα PROTAC examples, while cIAP1 and SCF-based systems have also been explored.
• Linker architecture: PEG, alkyl, ether, and heterocyclic structures have all been investigated. Their effects depend on ternary-complex geometry, metabolic stability, and cellular exposure.
• Alternative recognition: ERE-PROTAC demonstrates that the DBD can be targeted without using an orthosteric ERα ligand.
• Emerging approaches: Molecular glue-based designs can recruit ERα-containing protein complexes, although biochemical ubiquitination should not be interpreted as proof of cellular protein degradation.

The reported DC₅₀ and D_max values should be interpreted within their original assay conditions. Differences in exposure time, receptor expression, assay technology, and experimental models prevent direct ranking of every compound using a single potency value.

LBD-Directed PROTAC Development for Wild-Type ERα

Target Site: The Orthosteric Ligand-Binding Pocket, Helix 12, and Solvent-Exposed Exit Vectors

The ERα LBD is a compact, predominantly α-helical domain that forms a hydrophobic ligand-binding cavity. Its three-layer helical sandwich contains the orthosteric estrogen-binding pocket, which is surrounded by helices H3, H5, H7, H8, H11, and H12. Several residues are important for ligand recognition, including Glu353, Arg394, and His524. These residues contribute to the hydrogen-bonding network that anchors estrogen-like and other ER-binding ligands within the pocket.

Helix 12 is particularly important for PROTAC development because it changes position according to the bound ligand. In the agonist conformation, H12 helps stabilize the active receptor structure and forms part of the AF-2 coactivator-binding surface. Antagonist binding can reposition H12 and interfere with coactivator recruitment. SERD-derived compounds may also promote receptor destabilization through changes in the conformational and surface properties of the LBD.

For bifunctional PROTAC design, the most important structural consideration is not simply finding a ligand that binds strongly to the orthosteric pocket. The ligand must also provide a solvent-exposed position from which the linker can extend without disrupting the essential interactions that anchor the warhead. Structural comparison of ERα-ligand complexes can help identify peripheral substituents suitable for linker installation. A practical design should preserve the hydrogen-bonding network around Glu353, Arg394, and His524 while maintaining an accessible exit vector for E3 recruitment.

Warhead Selection: SERM-Derived, SERD-Derived, and Steroidal ERα Binders

SERM-derived ligands provide an important starting point for ERα PROTAC development. Raloxifene and lasofoxifene contain aromatic frameworks that interact with the ERα ligand-binding pocket and offer opportunities for structural modification. ERD-308 demonstrates the use of a raloxifene-derived warhead connected to a VHL ligand. ARV-471 provides another example of a lasofoxifene-based ER-binding scaffold connected to a CRBN recruiter.

SERM-derived warheads should be evaluated for their ability to retain target recognition after linker attachment. Their antagonist behavior can be useful because it reduces the likelihood of simply reproducing estrogen-like receptor activation. However, the parent ligand's antagonist activity does not establish that its PROTAC conjugate will produce efficient degradation.

SERD-derived ligands provide another useful starting point. AZ'6421 was developed from an AZD9496-derived ERα-binding core connected to a VHL recruiter. This approach takes advantage of an established ER-binding scaffold and modifies its peripheral chemical structure to accommodate linker attachment. One important consideration is that some SERD-derived warheads can induce ERα downregulation independently of the recruited E3 ligase. Consequently, the complete PROTAC should be compared with the parent warhead and an E3-inactive control to distinguish intrinsic SERD-like activity from additional PROTAC-mediated degradation.

Steroidal ligands, including estradiol-derived structures, can also provide high-affinity ERα recognition. Their rigid steroid framework may offer a useful structural starting point, but the ligand's agonist properties, substitution position, and conformational effects must be assessed before incorporating an E3 recruiter.

• SERM-derived warheads: prioritize raloxifene- or lasofoxifene-related structures when their binding mode and peripheral modification sites are compatible with conjugation.
• SERD-derived warheads: consider AZD9496-related or other degradation-associated ERα scaffolds, while separating intrinsic receptor downregulation from E3-dependent degradation.
• Steroidal warheads: evaluate estradiol-derived ligands when their receptor recognition and available linker attachment positions support bifunctional modification.
• Essential comparison: measure the parent ligand, linker-bearing intermediate, and final PROTAC separately to confirm retained ERα engagement.

Linker Design: Attachment Position, Length, Rigidity, and Polarity

The ERα PROTAC examples demonstrate that linker optimization can substantially change degradation performance. In AZ'6421 development, a series of PEG-containing linkers was evaluated, and a linker containing three PEG monomers produced strong ERα degradation in the reported assay. Subsequent optimization replaced the initial PEG-rich structure with alternative ether-containing architectures. This work showed that a linker can provide favorable degradation geometry but still introduce metabolic liabilities that affect the performance of the complete molecule.

ARV-471 illustrates a different approach. Its lasofoxifene-derived ER-binding component is connected to a CRBN recruiter through a linker containing nitrogen-rich heterocyclic elements, including piperidine- and piperazine-based structural features. Such constrained architectures can help control the relative orientation of the two binding units and reduce the conformational freedom of the linker.

• Attachment position: prioritize solvent-exposed substituents that do not disrupt the ligand's key hydrogen bonds or hydrophobic interactions within the ERα pocket.
• Linker length: prepare short, intermediate, and longer matched analogues. The three-unit PEG linker used during AZ'6421 optimization provides a research precedent, not a universal ERα linker length.
• Rigidity: compare flexible PEG or alkyl chains with heterocyclic structures such as piperidine and piperazine. Retain conformational restrictions only when they improve the complete degrader's geometry and activity.
• Polarity: balance ether and nitrogen content against molecular size, hydrogen-bonding capacity, solubility, and cellular exposure.
• Metabolic stability: evaluate linker cleavage and oxidation because degradation products may retain ERα-binding activity and compete with the intact PROTAC.

E3 Ligase Selection: CRBN, VHL, and Alternative Recruiters for ERα Degradation

CRBN and VHL are the principal E3 ligase systems to prioritize for conventional ERα PROTAC development. Their use is supported by different representative molecular architectures. ERD-308 and AZ'6421 use VHL-recruiting ligands, whereas ARV-471 and ERD-12310A demonstrate CRBN-based recruitment.

VHL recruitment is a useful starting point when the ERα warhead and linker provide a suitable orientation for assembling the ERα-PROTAC-VHL ternary complex. The AZ'6421 example also demonstrates that the intrinsic affinity of an E3 ligand should not be considered independently of the complete ternary system. A recruiter with favorable binary binding may still produce different degradation outcomes depending on linker geometry and the accessible surface of ERα.

CRBN provides a complementary option. Thalidomide-, lenalidomide-, and related glutarimide-based ligands can be used to construct CRBN-recruiting ERα degraders. The ERD-12310A research also demonstrates that modifications to the CRBN-binding component can influence the degradation performance of the complete molecule.

• VHL: use VH032- or AHPC-derived ligands as reference recruiters for comparing linker length, orientation, and ternary-complex formation.
• CRBN: evaluate thalidomide- or lenalidomide-derived recruiters when the attachment position and molecular properties are compatible with the ERα warhead.
• Alternative E3 systems: cIAP1- and SCF-associated strategies can be considered as exploratory comparators, but their performance should be demonstrated independently in the intended model.
• Recruiter validation: compare E3 expression, target ubiquitination, and degradation dependence rather than selecting an E3 ligand solely according to its reported affinity.

Table 3. LBD-Directed ERα PROTAC Design Recommendations and Research Precedents.

Mutation-Targeted PROTAC Development for ESR1 LBD Mutants

Target Site: Conformational Consequences of Y537, D538, E380, and L536 Mutations

ESR1 mutations can change the structural environment of the ERα ligand-binding pocket and alter its conformational equilibrium. Y537 and D538 are particularly important because they are located in or close to helix 12, which controls the transition between active and inactive receptor conformations. Y537S, Y537C, and Y537N can stabilize an agonist-like receptor state, while D538G can also favor ligand-independent activation. These changes can reduce the effectiveness of ligands that depend on the wild-type receptor conformation.

E380Q and L536P provide additional examples of mutation-associated structural changes. E380 is located in the LBD helical framework and contributes to the local environment surrounding ligand recognition. L536 is close to the C-terminal region and helix 12, where substitutions can influence receptor conformation and ligand-dependent interactions. Other alterations, including V422del, have also been examined in ERα degrader research.

For PROTAC development, the critical issue is that a mutation may affect more than the binary interaction between the ERα warhead and its target. It can also change the position of the attached linker, the accessibility of nearby protein surfaces, and the geometry of the ternary complex. Structural evaluation should therefore compare wild-type and mutant ERα rather than assuming that a warhead optimized against the wild-type protein will maintain identical degradation activity across all variants.

Warhead Selection: Mutation-Tolerant Versus Mutation-Selective ERα Ligands

A mutation-tolerant warhead is a practical starting point when the development objective is to maintain ERα degradation across several ESR1 variants. The lasofoxifene-derived warhead used in ARV-471 provides an important precedent. Research has reported degradation of Y537S and D538G receptor variants, with additional studies demonstrating activity against Y537C, Y537N, E380Q, L536P, and V422del under different experimental conditions.

The design objective should not be to maximize binding affinity against wild-type ERα alone. Instead, the warhead should maintain a compatible binding mode across the intended mutation panel. A ligand with slightly reduced wild-type affinity may still be useful if it retains sufficient mutant recognition and produces more consistent degradation.

• Mutation-tolerant strategy: prioritize ligands with demonstrated degradation across multiple ESR1 variants and evaluate whether their binding poses remain compatible with mutant structures.
• Mutation-selective strategy: consider targeted chemical modifications when a particular mutation creates a distinct pocket environment or changes local steric accessibility.
• Warhead comparison: evaluate lasofoxifene-derived and other antagonist-based scaffolds rather than assuming that a single ERα ligand will cover every mutation.
• Binding verification: compare parent ligands and linker-bearing intermediates against the same wild-type and mutant receptor panel.

Linker Design: Preserving Degradation Across Wild-Type and Mutant ERα

Mutations around helix 12 can alter the relative orientation of the ligand-binding pocket and the surrounding receptor surface. This means that the same warhead may present its linker attachment point differently in wild-type and mutant ERα. A linker that supports productive E3 recruitment in one receptor form may therefore become less effective in another.

Linker optimization should begin with a matched series in which the warhead and E3 recruiter remain constant while linker length and composition are varied. If a mutation retains warhead binding but shows weaker degradation, the next step should be to examine ternary-complex geometry and target ubiquitination rather than immediately replacing the warhead.

• Mutation-compatible exit vectors: prioritize attachment positions that remain solvent-accessible across wild-type and mutant structures.
• Length optimization: compare short, intermediate, and longer linkers to identify a distance that supports E3 access across different receptor conformations.
• Conformational control: evaluate flexible PEG/alkyl chains against partially rigid heterocyclic linkers to determine whether the mutant receptor requires a different linker trajectory.
• Parallel degradation profiling: measure DC₅₀ and D_max separately for wild-type and mutant ERα rather than using a single representative receptor model.

E3 Ligase Selection: Matching E3 Recruitment to Constitutively Active ERα Mutants

E3 ligase selection should be considered independently from mutant warhead recognition. A PROTAC may retain its ability to bind a mutant ERα protein but still show reduced degradation because the complete ternary complex is less favorable. This can occur when the altered receptor conformation changes the direction of the linker or the accessibility of ubiquitination sites.

CRBN and VHL provide useful comparison systems for mutant ERα programs. CRBN recruitment is supported by ARV-471 and ERD-12310A, while VHL-recruiting degraders such as AZ'6421 provide an alternative reference architecture. Comparing both systems can help identify whether a mutant-specific degradation limitation is associated with the warhead, linker geometry, or E3 recruitment.

• CRBN comparison: evaluate whether the mutant receptor can form a productive ternary complex with a CRBN-recruiting degrader.
• VHL comparison: investigate alternative receptor orientations and ubiquitination patterns using a VHL recruiter.
• Expression context: assess the abundance and activity of the selected E3 ligase in the experimental system.
• Mechanism confirmation: verify E3 dependence and receptor ubiquitination to distinguish poor mutant recognition from inefficient downstream degradation.

Table 4. Mutation-Targeted ERα PROTAC Design Recommendations.

Covalent PROTAC Development for ERα

Target Site: Cys530 and Other Addressable Residues in the ERα Ligand-Binding Pocket

Covalent ERα ligand design provides an alternative approach to achieving persistent target engagement. An important structural opportunity is Cys530, a nonconserved cysteine located near the end of helix 11 within the ERα ligand-binding pocket. This residue can be accessed in an appropriate antagonist-like receptor conformation and provides a defined site for electrophilic ligand development.

H3B-5942 provides a research precedent for this strategy. Its indazole-based recognition scaffold anchors within the ERα LBD, while a side-chain linker positions a Michael acceptor near Cys530. Structural and mass-spectrometry studies demonstrated covalent modification of this residue, including in an ERα Y537S mutant background. This example shows how an ERα-binding scaffold can be modified to establish residue-specific covalent engagement.

Importantly, H3B-5942 is a covalent ERα antagonist rather than a validated Cys530-directed PROTAC. Its structure provides a starting point for considering covalent warhead design, but the addition of an E3-recruiting ligand introduces new requirements. The modified molecule must retain Cys530 engagement while allowing the E3 ligase to approach the receptor in a productive orientation.

Warhead Selection: Acrylamide and Michael Acceptor Electrophiles Built on LBD Binders

A covalent ERα PROTAC warhead can be designed by combining an LBD-recognition scaffold with an appropriately positioned electrophilic group. Michael acceptors are particularly relevant because the Cys530-directed ligand precedent demonstrates how an electrophilic center can be oriented toward a specific receptor residue.

An acrylamide or related Michael acceptor should not be selected solely according to its intrinsic reactivity. The surrounding ERα-binding scaffold determines whether the electrophile can reach Cys530 with suitable geometry. A ligand with excessive nonspecific reactivity may modify unrelated cysteine-containing proteins, while an electrophile positioned too far from the target residue may show insufficient covalent engagement.

• Electrophile selection: consider acrylamide and other Michael acceptor structures when the ERα-binding scaffold can position the reactive center near Cys530.
• Recognition scaffold: retain the key LBD interactions that orient the ligand within the orthosteric pocket.
• Residue selectivity: evaluate covalent modification against C530S controls and other accessible cysteine-containing proteins.
• Reaction behavior: compare covalent engagement rate, extent of modification, and nonspecific reactivity rather than relying only on equilibrium binding affinity.

Linker Design: Positioning the Electrophile While Preserving Ternary Complex Formation

Covalent PROTAC design requires careful separation of the two structural functions of the molecule. The target-binding scaffold and electrophile must position the reactive group correctly for Cys530 engagement, while the E3-directed linker must extend toward the recruited ligase without disrupting that covalent interaction.

The Cys530-directed ligand structure provides a useful example of controlling electrophile orientation through a flexible side-chain linker and internal hydrogen-bonding interactions. For PROTAC development, an additional linker connection should preferably be introduced at a solvent-exposed position that does not interfere with the electrophilic center or the core ERα recognition elements.

• Separate functional vectors: preserve the direction of the Cys530-reactive group while identifying an independent E3-linker attachment position.
• Linker length: compare several spacer lengths to determine whether the covalently engaged receptor can accommodate the recruited E3 ligase.
• Linker composition: evaluate PEG, alkyl, and heterocyclic segments for their effects on solubility, steric accessibility, and ternary-complex formation.
• Target modification: confirm that covalent engagement does not prevent the receptor from presenting accessible ubiquitination sites.

E3 Ligase Selection: E3 Choice and Turnover Requirements for Covalent ERα Degraders

No directly validated Cys530-directed ERα covalent PROTAC architecture is established by the research examples discussed here. Consequently, E3 selection should be approached as a development question rather than an established structure-selection rule.

VHL and CRBN are reasonable initial comparison systems because both have demonstrated compatibility with conventional ERα PROTAC architectures. VHL can be evaluated using VH032- or AHPC-derived ligands, while CRBN recruitment can be explored using thalidomide- or lenalidomide-derived structures. However, the appropriate choice will depend on the orientation of the covalently engaged receptor and the accessibility of its ubiquitination surfaces.

• VHL recruitment: assess whether a VHL ligand can be connected without disturbing the Cys530-reactive warhead.
• CRBN recruitment: use as a complementary E3 system to determine whether a different ternary-complex orientation improves ubiquitination.
• Target turnover: distinguish persistent covalent target engagement from productive ubiquitination and actual protein degradation.
• Mechanistic controls: compare covalent and noncovalent analogues, electrophile-inactive controls, and E3-inactive controls.

Table 5. Design Considerations for Covalent ERα PROTAC Development.

Allosteric-Site-Targeted PROTAC Development for ERα

Target Site: The AF-2/Coactivator Binding Groove and Alternative ERα Surface Interfaces

The ERα AF-2 region provides an important surface for investigating PROTAC designs that do not rely exclusively on the orthosteric ligand-binding pocket. AF-2, also known as the coactivator binding site (CABS), is formed by helices H3, H4, H5, and H12. It recognizes short LXXLL motifs within nuclear receptor coactivators and is stabilized by a charged interaction network involving Lys362 and Glu542.

Unlike the buried orthosteric ligand-binding pocket, the AF-2 surface is an exposed protein-protein interaction groove. Its accessibility depends on the receptor's conformational state because helix 12 can occupy or expose the coactivator-binding region. This makes receptor conformation an important consideration when selecting an AF-2-directed recognition element.

Another ERα surface of interest is an AF-2-independent peptide-binding site located on the β-hairpin face of the LBD. Structural studies have demonstrated that an ERα-specific peptide can recognize this shallow surface independently of the classical coactivator-binding groove. Although this interaction has not established a mature PROTAC platform, it provides an alternative recognition concept for targeting exposed ERα protein-interaction surfaces.

A further development direction comes from the 14-3-3/ERα F-domain interface. A 2026 molecular glue-based PROTAC study connected the 14-3-3/ERα interaction stabilizer FC-NAc to the VHL ligand VH032. This design recruits a composite protein interface rather than directly occupying the conventional ERα LBD. It provides an important proof-of-concept for targeting partially disordered ERα regions through induced protein-protein interactions.

Warhead Selection: LXXLL-Mimetic Peptides, Small-Molecule CBS Binders, and Dual LBP/CBS Ligands

LXXLL-mimetic peptides are a logical starting point for AF-2-directed ligand development because they reproduce the recognition motif used by natural coactivators. Their hydrophobic leucine residues interact with the AF-2 groove, while surrounding residues contribute to binding orientation and receptor selectivity. A peptide-derived warhead can therefore provide a direct recognition element for a surface that is not accessible through conventional orthosteric ligands.

Small-molecule coactivator-binding site inhibitors (CBIs) provide an alternative. Representative research scaffolds include pyrimidine-based ligands, guanylhydrazone structures, and benzimidazole derivatives. These compounds have been investigated for their ability to disrupt ERα-coactivator interactions. However, many reported CBIs have relatively modest binding or functional potency, reflecting the difficulty of targeting a broad, relatively shallow protein-interaction surface.

Dual LBP/CBS ligands offer another design concept. Research has connected an ERα LBD-binding scaffold to a coactivator-binding site inhibitor through a flexible diaminoalkyl spacer. These heterodimeric molecules can simultaneously engage the orthosteric ligand-binding site and the coactivator surface. Importantly, the reported compounds acted as ERα antagonists without reducing ERα protein abundance. They should therefore be regarded as dual-site ligand design precedents rather than validated PROTAC degraders.

The FC-NAc-based MGPROTAC provides a different approach. Instead of using an isolated ERα ligand, FC-NAc stabilizes the interaction between 14-3-3 and the partially disordered ERα F-domain. The resulting composite interface can be connected to a VHL recruiter. This design is particularly relevant when a conventional ligandable pocket is unavailable or difficult to exploit.

• AF-2-directed peptides: investigate LXXLL-based or optimized peptide motifs when the coactivator-binding groove provides a suitable recognition surface.
• Small-molecule CBIs: evaluate pyrimidine, guanylhydrazone, and benzimidazole-based structures as starting points for surface-binding warheads.
• Dual-site ligands: use LBP/CBS conjugates as structural precedents, while confirming that the resulting molecule produces degradation rather than antagonism alone.
• Complex-stabilizing molecular glues: consider FC-NAc-related structures for recruiting the 14-3-3/ERα composite interface.

Linker Design: Connecting a Surface-Bound Warhead to the E3 Recruiter

Linker design is particularly important for allosteric and protein-interaction-surface PROTACs because the recognition element is often attached to an exposed receptor surface rather than positioned within a deep pocket. The attachment point must allow the E3 recruiter to extend away from the target surface while maintaining the interactions that stabilize the warhead-bound state.

For peptide-based designs, the linker should be attached through a position that does not interfere with the LXXLL recognition motif or the peptide's preferred secondary structure. Flexible PEG and alkyl segments can be compared initially, followed by more conformationally restricted structures if the first-generation conjugates show poor ternary-complex formation.

The 2026 FC-NAc-based MGPROTAC study provides a direct example of linker-dependent behavior. A short PEG linker containing five heavy atoms was insufficient for effective VHL recruitment. Extending the linker improved cooperative complex formation, while an approximately 11-heavy-atom alkyl linker in CV2a provided strong cooperative recruitment and biochemical ubiquitination. A longer 17-heavy-atom alkyl linker showed substantially weaker apparent binding in the reported system. However, despite biochemical ubiquitination, CV2a did not measurably reduce ERα protein levels in the tested cells.

• Attachment position: use solvent-exposed positions on peptide or small-molecule surface binders that preserve their key protein-interaction contacts.
• Spacer length: prepare a focused length series rather than assuming that longer linkers improve E3 access.
• Linker composition: compare PEG and alkyl structures because linker chemistry can affect cooperativity, cellular permeability, and ubiquitination orientation.
• Complex stability: evaluate the lifetime and cooperativity of the complete protein-protein interaction complex rather than measuring binary binding alone.

E3 Ligase Selection: VHL and CRBN Recruitment From Allosteric ERα Warheads

VHL provides the most direct research precedent for ERα complex-directed surface recruitment through the FC-NAc-based MGPROTAC. VH032 was connected to the molecular glue through different linker structures, allowing researchers to investigate how the recruited VHL complex interacts with the 14-3-3/ERα assembly.

The study also demonstrated that strong biochemical ubiquitination does not necessarily produce measurable degradation in cells. Although the optimized MGPROTAC promoted ubiquitination of the 14-3-3/ERα complex, ERα protein levels were not measurably reduced in the reported cellular experiments. This distinction highlights the need to evaluate cellular access, complex lifetime, and productive ubiquitination separately.

CRBN provides an alternative E3 recruitment system for future surface-directed ERα designs, but its compatibility with individual AF-2 or β-hairpin warheads requires experimental evaluation. The selected recruiter must support a productive orientation without disrupting the surface interaction that anchors the target-binding component.

• VHL: prioritize as a research-supported comparator for 14-3-3/ERα complex-directed designs.
• CRBN: evaluate as an alternative recruiter for peptide or small-molecule surface-binding warheads.
• Cooperativity: determine whether the recruited E3 improves complex stability and ubiquitination rather than relying on binary ligand affinity.
• Cellular confirmation: establish that ubiquitination results in measurable ERα protein reduction in the intended model.

Table 6. Allosteric and Surface-Directed ERα PROTAC Design Options.

DBD-Targeted PROTAC Development for LBD-Independent ERα Degradation

Target Site: ERα DNA-Binding Domain, ERE-Contact Surface, and Dimerization Interface

The ERα DBD is a compact structural region containing two zinc-finger motifs. These motifs coordinate zinc ions through conserved cysteine residues and help maintain the three-dimensional structure required for DNA recognition. The first zinc finger contributes to sequence-specific ERE recognition, while the second supports receptor-DNA interactions and receptor dimerization.

Unlike the orthosteric LBD pocket, the DBD recognizes a DNA sequence through an extended protein-DNA interaction surface. This creates a different opportunity for degrader design: instead of using a conventional small-molecule receptor ligand, a nucleic acid sequence can act as the target-recognition component.

The estrogen response element provides a particularly relevant recognition unit because it is naturally recognized by ERα through its DBD. Targeting this region can avoid direct dependence on the LBD conformation and therefore offers an alternative approach for investigating receptor degradation when conventional ligand-binding interactions are compromised.

Warhead Selection: ERE Oligonucleotide, Aptamer, and DBD-Binding Peptide Ligands

ERE oligonucleotides provide the most direct research-supported starting point for DBD-directed ERα PROTAC development. In a published ERE-PROTAC design, a modified ERE DNA sequence was connected to VH032 through copper-catalyzed azide-alkyne cycloaddition. The ERE component recognized ERα through the DBD, while VH032 recruited VHL.

This strategy demonstrates that nucleic acid recognition can be incorporated into a PROTAC architecture. However, the ERE sequence is larger and more chemically complex than a conventional small-molecule warhead. Its sequence, secondary structure, chemical modification, and binding specificity therefore require careful optimization.

Aptamers and DBD-binding peptides are additional exploratory recognition options. An aptamer could provide a structured nucleic acid ligand that recognizes a specific ERα surface, while a peptide could be designed to interact with the DBD or its surrounding protein-interaction interface. However, these approaches should not be presented as established ERα PROTAC platforms without direct binding and degradation evidence.

• ERE oligonucleotide: prioritize as the direct research precedent for DBD-directed ERα recognition.
• Aptamer ligands: explore when a sequence-specific ERα-binding nucleic acid can be identified and independently validated.
• Peptide ligands: consider interface-derived peptides when the DBD provides an accessible protein-recognition surface.
• Recognition specificity: verify that the selected sequence or peptide binds ERα rather than producing nonspecific nucleic acid or protein interactions.

Linker Design: Conjugation Chemistry, Spacer Length, and Orientation for Nucleic Acid Warheads

Nucleic acid-based PROTACs require a conjugation strategy that preserves both the DNA recognition function and E3 ligand activity. In the ERE-PROTAC example, the 5′ terminus of the ERE sequence was modified with an azide group, while the VHL ligand was functionalized with a terminal alkyne. Copper-catalyzed azide-alkyne cycloaddition then connected the two components.

This approach provides a useful design framework because the attachment position can be selected independently from the DNA bases responsible for receptor recognition. Nevertheless, linker length and orientation remain important. A spacer that is too short may prevent the E3 ligase from approaching the DBD-bound receptor, whereas excessive length may increase molecular flexibility and complicate cellular delivery.

• Conjugation position: prioritize terminal modification of the ERE oligonucleotide to minimize interference with its receptor-binding sequence.
• Click-compatible chemistry: use complementary azide and alkyne functional groups for controlled assembly when compatible with the selected warhead and recruiter.
• Spacer length: compare short and intermediate PEG or alkyl spacers to identify a productive distance between ERα and VHL.
• Oligonucleotide properties: consider nuclease stability, molecular size, charge, solubility, and intracellular availability.
• Orientation: preserve ERE recognition while allowing the E3 ligand to access the receptor without steric interference.

E3 Ligase Selection: Recruiters Compatible With DBD-Engaged ERα

VHL is the directly demonstrated E3 ligase recruiter in the reported ERE-PROTAC design. VH032 was selected as the small-molecule E3 ligand and connected to the ERE recognition sequence through click chemistry. The resulting construct demonstrated reversible ERα degradation through a DBD-directed recognition mechanism.

CRBN can be considered as an alternative E3 system for future nucleic acid-based ERα degraders. However, replacing VH032 with a CRBN recruiter would require independent optimization because the larger nucleic acid recognition unit may impose different steric and physicochemical constraints.

• VHL: use VH032 as the research-supported reference recruiter for ERE-based ERα PROTACs.
• CRBN: explore as an alternative when a suitable conjugation position and molecular architecture can be identified.
• Ligase accessibility: evaluate whether the selected E3 can approach the DBD-bound receptor without interfering with DNA recognition.
• Degradation verification: distinguish ERE-mediated transcriptional inhibition from actual ubiquitination and protein depletion.

Table 7. DBD-Targeted ERα PROTAC Design Recommendations.

Variant-Targeted PROTAC Development for ERα Splice Variants and Truncated Forms

Target Site: Regions Retained by ERα36, ERα46, and Other Truncated ERα Forms

ERα splice variants present a different target-selection challenge because alternative splicing can remove or replace specific receptor domains. ERα46 lacks approximately the first 173 amino acids of full-length ERα, including the AF-1 region. However, it retains the DBD, hinge, and conventional LBD/AF-2 regions. Consequently, LBD-directed warheads may remain suitable starting points for ERα46 degradation, although the altered N-terminal structure can influence receptor interactions and localization.

ERα36 has a more substantial structural difference. It lacks both AF-1 and AF-2 and contains a unique C-terminal sequence that replaces the corresponding portion of the full-length receptor. It retains the DBD and part of the LBD, but its ligand-binding region is not equivalent to the complete canonical ERα66 pocket. ERα36 has also been associated with membrane-proximal signaling, which introduces additional considerations for intracellular degrader accessibility.

These differences mean that a PROTAC designed against full-length ERα cannot automatically be assumed to degrade ERα36 and ERα46. The first development step should be to identify the exact receptor sequence and determine which structural regions remain available for ligand recognition.

Warhead Selection: Ligands That Engage ERα Without an Intact AF-2 Pocket

For ERα46, conventional LBD-directed warheads remain a reasonable starting point because the receptor retains its LBD and AF-2 region. SERM- or SERD-derived ligands can therefore be evaluated, provided that binding and degradation are confirmed against the specific isoform.

For ERα36, a DBD-directed recognition strategy may provide a more independent starting point. The ERE-PROTAC concept is particularly relevant because its recognition unit binds the DBD rather than relying on the complete orthosteric LBD pocket. Since ERα36 retains the DBD, this approach provides a structural rationale for exploring its degradation.

However, direct degradation data for ERα36- or ERα46-specific PROTACs should not be inferred from studies involving full-length ERα. Each variant requires independent recognition and degradation validation.

• ERα46: prioritize LBD-binding ligands and compare their performance with full-length ERα.
• ERα36: investigate DBD-directed recognition and other ligands that do not depend on an intact AF-2 region.
• Sequence-specific design: confirm which amino acid regions are retained before selecting a warhead.
• Variant selectivity: evaluate degradation of the intended isoform separately from full-length ERα and other receptor forms.

Linker Design: Reaching Both Nuclear and Membrane-Proximal ERα Pools

Receptor localization can influence PROTAC performance because the target and recruited E3 ligase must occupy compatible intracellular compartments. Full-length ERα is primarily associated with nuclear receptor activity, although it can also participate in membrane-associated signaling. ERα46 and ERα36 have different domain compositions and can show distinct subcellular distributions.

Linker optimization should therefore consider more than the distance between the warhead and E3 ligand. The complete degrader must remain accessible to the receptor in its intended cellular compartment. Linker polarity, molecular size, flexibility, and cellular permeability can all influence whether the compound reaches the relevant receptor population.

• Compartment compatibility: assess whether the selected E3 recruiter and ERα variant are accessible within the same intracellular region.
• Linker polarity: balance hydrophilic and lipophilic components to maintain adequate cellular exposure.
• Conjugation geometry: preserve the binding orientation of the selected variant-specific warhead.
• Uptake assessment: measure intracellular availability rather than assuming that activity against ERα66 predicts activity against truncated forms.

E3 Ligase Selection: Matching E3 Recruitment to Non-Canonical ERα Localization

CRBN and VHL provide practical starting points for ERα variant-directed PROTAC development, but their suitability should be assessed in the context of the intended receptor localization. A recruiter that performs well against nuclear ERα66 may not necessarily provide the same degradation efficiency against a membrane-proximal receptor population.

E3 expression and accessibility should therefore be evaluated alongside receptor localization. If the target variant and E3 recruiter do not have sufficient spatial compatibility, changing the warhead alone may not solve the degradation limitation. In such cases, alternative E3 recruitment strategies or modified molecular architectures may need to be investigated.

• CRBN: evaluate receptor degradation and E3 accessibility in the intended variant-expressing system.
• VHL: compare VHL recruitment when the target localization and ternary-complex geometry support productive engagement.
• Spatial compatibility: examine the distribution of ERα variants and E3 components rather than relying only on total protein abundance.
• Isoform-resolved analysis: measure ERα66, ERα46, and ERα36 separately to determine which receptor forms are depleted.

Table 8. ERα Splice Variant-Targeted PROTAC Design Recommendations.

Subtype-Selective PROTAC Development for ERα over ERβ and Related Nuclear Receptors

Target Site: Residue Differences Between the ERα and ERβ Ligand-Binding Domains

ERα and ERβ share a similar overall nuclear receptor architecture, and their DBD and LBD regions are highly conserved. However, differences in amino acid composition and pocket geometry can influence ligand orientation and receptor selectivity. These differences provide opportunities to develop ERα-selective warheads that minimize recognition of ERβ.

Several LBD residues are particularly relevant to this design objective. For example, ERα Leu384 corresponds to Met336 in ERβ, while ERα Met421 corresponds to Ile373 in ERβ. These substitutions change local steric volume and pocket geometry, which can influence how larger ligand structures fit into the two receptor subtypes.

Subtype selectivity should therefore be considered during initial warhead selection rather than being treated as a property that can automatically be introduced by adding a linker or E3 ligand. A ligand with favorable ERα binding but substantial ERβ recognition may produce unwanted degradation of both receptor subtypes.

Warhead Selection: Chemotypes With an ERα-Over-ERβ Binding Preference

The preferred strategy is to identify ERα-binding scaffolds that exploit subtle differences in the ligand-binding pockets. Larger or appropriately substituted aromatic structures may interact differently with ERα and ERβ because of the distinct side-chain volumes and conformational flexibility surrounding the binding cavity.

Research on ERα-selective ligands has demonstrated that structural optimization can produce measurable subtype preferences. For example, a benzoxepine-based LBD ligand was reported to show approximately 5.3-fold ERα selectivity. Related dual LBP/CBS antagonist structures also demonstrated stronger functional antagonism toward ERα than ERβ in the reported assays. These findings provide useful ligand design precedents, but they do not establish that the same compounds function as selective ERα PROTAC warheads.

• ERα-selective LBD binders: prioritize chemotypes that exploit local pocket differences around residues such as Leu384 and Met421.
• Substituent optimization: modify peripheral aromatic or heterocyclic groups to improve steric complementarity with ERα.
• Alternative surface recognition: consider ERα-selective peptide-binding surfaces when conventional LBD selectivity is insufficient.
• Comparative profiling: measure binding to ERα and ERβ independently before evaluating degradation selectivity.

Linker Design: Using Linker Geometry to Amplify Subtype Selectivity

Linker geometry can influence the selectivity of a complete PROTAC because ERα and ERβ may present different receptor surfaces after binding the same warhead scaffold. A linker attachment position that supports productive ternary-complex formation with ERα may produce a less favorable orientation with ERβ.

However, linker geometry should be considered an additional optimization variable rather than a substitute for selective target recognition. If the parent warhead binds both receptor subtypes with similar affinity, changing linker length alone may not produce a sufficiently selective degradation profile.

• Attachment position: compare solvent-exposed warhead substituents that preserve ERα-selective binding interactions.
• Linker length: investigate whether different receptor surface orientations favor particular spacer lengths.
• Conformational control: compare flexible and rigid linkers to identify ternary-complex geometries that favor ERα.
• Parallel testing: evaluate ERα and ERβ binding, ubiquitination, and protein degradation using matched experimental conditions.

E3 Ligase Selection: Limiting Co-Degradation of Related Nuclear Receptors

E3 ligase selection does not independently determine whether a PROTAC recognizes ERα or ERβ. The primary source of subtype selectivity is the target-binding ligand and the resulting ternary-complex geometry. Nevertheless, E3 recruitment can influence the overall degradation profile by changing the orientation, stability, and accessibility of the recruited receptor.

CRBN and VHL can be evaluated as alternative recruiters for ERα-selective warheads. Their effects should be compared using both receptor subtypes because a change in E3 recruitment may improve ERα degradation without necessarily reducing ERβ engagement.

• CRBN: compare ERα and ERβ degradation using matched CRBN-recruiting structures.
• VHL: investigate whether alternative ternary-complex geometry improves the ERα-to-ERβ degradation ratio.
• Off-target assessment: evaluate other nuclear receptors and potential E3-related protein changes.
• Selectivity confirmation: compare receptor binding and protein depletion separately rather than relying on ligand affinity alone.

Table 9. ERα-Selective PROTAC Design Recommendations.

Why Do ERα PROTACs Fail? Common Failure Modes and Optimization Directions

ERα PROTAC development involves several interconnected variables. A compound may bind the receptor effectively but fail to induce sufficient ubiquitination, or it may produce strong degradation in a biochemical or cellular assay while showing poor performance under different experimental conditions. Successful optimization therefore requires separating target recognition, ternary-complex formation, E3 recruitment, intracellular exposure, and downstream protein depletion.

High Affinity but Weak Degradation: Poor Ternary Complex Cooperativity

Strong ERα binding does not guarantee productive degradation. A PROTAC must simultaneously engage ERα and the selected E3 ligase in a geometry that allows ubiquitin transfer to accessible lysine residues. If the ternary complex is unstable or adopts an unfavorable orientation, target binding may occur without sufficient ubiquitination.

One common mistake is to improve the affinity of the ERα warhead repeatedly without investigating the complete ternary system. A stronger target-binding interaction may not correct an unfavorable linker trajectory or steric conflict between the receptor and E3 ligase.

• Confirm ternary-complex formation: compare binary binding with ternary-complex formation using suitable biochemical or biophysical assays.
• Optimize linker geometry: investigate alternative attachment positions, lengths, and conformational constraints.
• Measure ubiquitination: determine whether the recruited E3 can modify the intended ERα protein.
• Compare E3 systems: evaluate CRBN and VHL when target engagement is retained but degradation remains weak.

Incomplete Degradation and the Hook Effect: Reading DC₅₀ and D_max Correctly

DC₅₀ and D_max describe different aspects of PROTAC activity. DC₅₀ represents the concentration required to achieve half of the maximum observed degradation, whereas D_max represents the maximum degradation level reached under the tested conditions. A compound with a low DC₅₀ may still be unsuitable if its D_max is insufficient for the intended research objective.

The hook effect is another important consideration. At excessive PROTAC concentrations, the target protein and E3 ligase may become occupied by separate PROTAC molecules rather than forming the productive ternary complex. This can reduce degradation at higher concentrations and produce a non-linear concentration-response relationship.

• Full concentration-response curves: measure both the increasing and decreasing portions of the degradation response.
• Time-course evaluation: compare degradation kinetics and receptor recovery after compound removal.
• Separate DC₅₀ and D_max: avoid selecting candidates based on potency values alone.
• Mechanistic interpretation: distinguish a hook effect from reduced exposure, target recovery, or inadequate E3 recruitment.

Permeability, Solubility, and Metabolic Liabilities of ERα Degraders

ERα PROTACs can have high molecular weights and multiple polar groups because they combine an ERα ligand, linker, and E3 recruiter. These properties can create challenges involving aqueous solubility, passive membrane permeability, intracellular exposure, and metabolic stability.

The AZ'6421 research provides an important example of a linker-related limitation. Although the optimized VHL-recruiting PROTAC demonstrated potent ERα degradation in vitro, metabolic instability of its linker generated metabolites that retained ERα-binding activity. These metabolites competed with the intact PROTAC and contributed to lower degradation than expected under the reported in vivo conditions.

The MGPROTAC research provides another example of the difference between biochemical activity and cellular performance. Despite demonstrating complex recruitment and ubiquitination in biochemical experiments, the optimized compound did not produce measurable ERα depletion in the reported cell-based experiments. Cellular access, competing protein interactions, and complex lifetime were identified as possible limitations.

• Solubility: optimize PEG content, ionizable groups, and overall molecular polarity without disrupting target binding.
• Permeability: compare molecular size, hydrogen-bonding capacity, and linker flexibility.
• Metabolic stability: identify linker oxidation and cleavage products that may retain target-binding activity.
• Intracellular exposure: confirm that the complete PROTAC reaches the intended ERα-containing compartment.

E3-Related Failures: Ligase Abundance, Off-Target Degradation, and Acquired Resistance

E3 ligase availability can influence ERα PROTAC activity. If the selected recruiter binds its intended E3 ligase but the ligase is insufficiently expressed or functionally available in the experimental system, productive degradation may remain limited. Differences in E3 expression can also explain why the same PROTAC produces different results across experimental models.

Off-target degradation is another consideration, particularly for CRBN-recruiting compounds. CRBN-binding ligands can alter the stability of other proteins, and these changes may complicate the interpretation of downstream cellular responses. In addition, resistance-associated ESR1 mutations or changes in receptor expression can reduce the performance of an otherwise effective warhead.

• Ligase abundance: profile CRBN or VHL expression and confirm that the selected E3 system is available in the intended model.
• Off-target analysis: evaluate changes in other proteins and distinguish ERα-dependent effects from recruiter-related effects.
• Mutation-associated resistance: test whether altered ESR1 sequences retain the intended warhead-binding mode.
• Mechanistic controls: use E3 competition, ligase perturbation, proteasome inhibition, and non-degrading control compounds where appropriate.

BOC Sciences Support for ERα PROTAC Development

ERα PROTAC development requires coordinated target assessment, ligand discovery, linker optimization, E3 recruitment, and degradation evaluation. BOC Sciences provides integrated research products and custom services to support these stages, from early structural feasibility analysis to the synthesis and characterization of optimized degrader candidates. Our ER-targeted PROTAC development support can be tailored to wild-type ERα, ESR1 mutants, splice variants, and alternative receptor-binding strategies.

ERα Target, Mutation, and Variant Feasibility Assessment

• Assess ERα66, ERα46, ERα36, and selected ESR1 mutant structures to define the intended receptor target.
• Identify retained domains, accessible ligand-binding surfaces, and potential recognition opportunities.
• Evaluate receptor expression and relevant E3 ligase availability in the intended research system.
• Provide target degradability assessment for TPD development to support early feasibility decisions.

ERα Warhead Discovery and Target Ligand Design

• Evaluate SERM-derived, SERD-derived, steroidal, covalent, and alternative ERα-binding ligand scaffolds.
• Identify solvent-exposed attachment positions and compare warhead modifications using structural analysis.
• Support ligand optimization for wild-type ERα, ESR1 mutants, and selected receptor variants.
• Provide warhead library access and ligand design for target proteins, supported by protein-ligand molecular docking.

Linker and E3 Ligase System Design With Custom PROTAC Synthesis

• Develop linker matrices covering PEG, alkyl, ether, aromatic, heterocyclic, and conformationally restricted structures.
• Optimize target-ligand attachment positions and linker properties through linker binding site selection and design and linker design and optimization services.
• Compare CRBN and VHL recruiter structures through CRBN ligand design, VHL ligand design, and E3 ligase system design.
• Support custom ERα PROTAC synthesis, purification, analytical characterization, and PROTAC scale-up production.

Mechanistic and Developability Evaluation of ERα Degraders

• Evaluate ERα binding, E3 recruitment, and ternary-complex formation using PROTAC ternary complex assays.
• Confirm receptor ubiquitination through protein ubiquitination services.
• Characterize degradation activity using degradation ability assays and PROTAC activity assays.
• Investigate cellular exposure and metabolic liabilities through PROTAC cellular permeability assays, PROTAC in vitro metabolism, and PROTAC in vitro evaluation.
• Support candidate comparison through PROTAC high-throughput screening.

Table 10. BOC Sciences Products and Building Blocks for ERα PROTAC Development.

In addition to the listed products, BOC Sciences provides a broad range of PROTAC raw materials, E3 ligase ligands, linker intermediates, and custom synthesis capabilities. Our team can help select suitable building blocks and develop a tailored ERα degrader strategy according to your target receptor form, preferred warhead, E3 ligase system, and research objectives.

Explore featured products that can expand your research options and accelerate your next discovery.

Access end-to-end service solutions that help bring efficiency, flexibility, and expertise to your research pipeline.

News

• Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology
• Degrader Building Blocks for Targeted Protein Degradation
• Recent Progress of PROTACs Targeting Non-enzymatic Functional Proteins
• Discovery of Molecular Glue Degraders

Technical Information

• Proteolysis-Targeting Chimeras (PROTAC)
• Targeted Protein Degradation: The Next Frontier in Drug Discovery
• Overview of 12 Targeted Protein Degradation Technologies
• Peptide and Small Molecule Based PROTACs Technology